How is insulin made
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
The Biosynthesis and Production of Insulin
Insulin Biosynthesis: Preproinsulin to Insulin
Preproinsulin Formation and Processing
Insulin is initially synthesized in the pancreatic β-cells as a single-chain precursor known as preproinsulin. This precursor contains an N-terminal signal sequence and a connecting peptide (C-peptide) that links the A and B chains of the insulin molecule . The signal sequence directs the nascent preproinsulin into the endoplasmic reticulum, where it is cleaved to form proinsulin. Proinsulin is then transported to the Golgi apparatus and packaged into secretory granules .
Conversion to Mature Insulin
Within the secretory granules, proinsulin undergoes specific proteolytic cleavage by prohormone convertases 1/3 and 2, and carboxypeptidase E, which remove the C-peptide, resulting in the formation of mature insulin composed of two polypeptide chains (A and B) linked by disulfide bonds. This mature insulin is stored in the granules as zinc-containing hexamers until it is secreted in response to glucose stimulation .
Chemical Synthesis of Insulin
Challenges in Chemical Synthesis
The chemical synthesis of insulin is complex due to its intricate structure, which includes 51 amino acids arranged in two chains connected by three disulfide bonds. The poor physicochemical properties of the individual chains and the hormone itself add to the challenge . Despite these difficulties, various strategies have been developed to chemically assemble insulin, enabling the correct folding of the two chains and selective formation of disulfide bonds .
Advancements in Synthesis Techniques
Early methods involved the separate synthesis of the A and B chains followed by their combination and folding in solution, which often resulted in low yields of correctly folded insulin. Modern techniques, such as solid-phase peptide synthesis (SPPS) and regioselective stepwise formation of disulfide bonds, have significantly improved the efficiency and yield of synthetic insulin . These advancements have facilitated the production of numerous insulin analogues with optimized structural and functional features .
Recombinant DNA Technology in Insulin Production
Recombinant Insulin Production
Recombinant DNA technology has revolutionized insulin production, making it possible to produce human insulin in large quantities using microbial systems. The first recombinant insulin was produced in bacteria (Escherichia coli) by expressing precursors of the A and B chains separately or as a single proinsulin precursor. Yeast (Saccharomyces cerevisiae) has also been used to produce insulin, offering advantages in post-translational modifications and protein folding .
Economic and Technical Considerations
The production of recombinant insulin involves significant technical complexity and high costs. Large-scale production requires substantial equipment and presents numerous scale-up challenges. Economic evaluations have highlighted the need for cost reduction strategies and environmental impact minimization to make insulin production more sustainable.
Future Prospects and Innovations
Emerging Production Systems
To meet the growing global demand for insulin, alternative production systems are being explored. Transgenic plants, for instance, offer a promising approach for producing insulin in a cost-effective manner. High levels of biologically active proinsulin can be expressed in plant seeds or leaves, providing a stable and scalable production platform.
Computational and Simulation Studies
Advances in computational methods, such as molecular dynamics simulations, are enhancing our understanding of insulin's conformational dynamics and interactions with its receptor. These insights are crucial for developing new synthetic insulin analogues with improved therapeutic properties.
Conclusion
The biosynthesis and production of insulin involve intricate biological and chemical processes. From the initial formation of preproinsulin in pancreatic β-cells to the advanced techniques in chemical synthesis and recombinant DNA technology, significant progress has been made in understanding and manufacturing this vital hormone. Ongoing research and innovation continue to improve the efficiency and scalability of insulin production, ensuring its availability for the growing number of diabetes patients worldwide.
Sources and full results
Most relevant research papers on this topic